Department of Otolaryngology-Head & Neck Surgery, Kobe City Medical Center General Hospital, Kobe 650-0047, Japan.
Department of Otolaryngology-Head & Neck Surgery, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.
Medicina (Kaunas). 2021 Dec 13;57(12):1361. doi: 10.3390/medicina57121361.
: To investigate clinicopathological characteristics and survival outcomes of patients with buccal cancer in Japan. : This study was conducted using a database of 1055 patients with oral cancers treated between 2010 and 2017 at 12 institutions in Japan. Ninety-two patients (8.7%) with primary buccal cancer were extracted and clinicopathological characteristics and survival outcomes were compared between patients with buccal cancers and patients with other oral cancers. : Ages were significantly higher in the patients with buccal cancer (73 years old vs. 69 years old). Buccal cancer had less advanced cT stage and cN stage than other oral cancers. Overall 5-year survival (OS) was 80.6%, and recurrence-free 5-year survival (RFS) of buccal cancers was 67.8%, and there were no significant differences in survival compared with other oral cancers in terms OS or RFS (5y-OS: 82.5%, 5y-RFS: 74.4%). However, patients with stage IV buccal cancer showed poorer prognosis in terms of OS and RFS compared with the same stage patients with other oral cancer. Advanced T stage was the only factor independently associated with both OS and RFS of patients with buccal cancer in this study. : Postoperative radiotherapy or chemoradiotherapy should be considered to improve survival outcome of buccal cancer patients, especially for the patients with advanced primary site disease or a higher cancer stage.
: 研究目的：调查日本颊癌患者的临床病理特征和生存结局。: 本研究使用了日本 12 家机构在 2010 年至 2017 年期间治疗的 1055 例口腔癌患者的数据库。从数据库中提取了 92 例（8.7%）原发颊癌患者，并比较了颊癌患者和其他口腔癌患者的临床病理特征和生存结局。: 颊癌患者的年龄明显高于其他口腔癌患者（73 岁 vs. 69 岁）。颊癌的 cT 分期和 cN 分期明显低于其他口腔癌。总 5 年生存率（OS）为 80.6%，颊癌的无复发生存率（RFS）为 67.8%，在 OS 和 RFS 方面与其他口腔癌相比，生存率无显著差异（5y-OS：82.5%，5y-RFS：74.4%）。然而，IV 期颊癌患者的 OS 和 RFS 预后较同分期其他口腔癌患者差。在本研究中，T 分期较晚是影响颊癌患者 OS 和 RFS 的唯一独立因素。: 对于颊癌患者，尤其是原发灶疾病较晚或癌症分期较高的患者，应考虑术后放疗或放化疗以改善生存结局。
